Mary Hames
Board Member, CURE NDD
Mary Hames is listed as Board Member, CURE NDD. Mary is scheduled to speak at Advanced Therapies Week 2027 on 19 January 2027.
Compiled from published conference agendas; not yet confirmed by Mary. Is this you? Claim this profile.
About
Mary Hames is a scientist-strategist with over 10 years transforming breakthrough science into clinical and commercial success across biotech and pharmaceutical companies. Her career spans R&D, medical affairs, diagnostics, clinical development, and executive leadership, with deep expertise in neurology, rare diseases, and radiopharmaceuticals—areas where scientific complexity meets patient urgency. Mary has guided teams from early development through launch readiness, building medical affairs functions, sharpening portfolio strategy, and aligning cross-functional teams for emerging biotechs and global pharma leaders alike. She excels at translating scientific nuance into strategic action for clinical development, evidence generation, and market access.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Panel: Building a sustainable commercial future for rare and nano-rare advanced therapies Speaker · 19 January 2027
- Session 3: How to ensure the long-term future of advanced therapies for rare, ultra-rare and nano-rare diseases? Speaker · 19 January 2027
Spoke alongside
People who have shared a session with Mary at events on B2DB.
- Samar Mohanty President & CSO · Nanoscope Therapeutics 2 shared sessions
- Kirsten Vonde Principal Consultant · Granzer Regulatory Consulting & Services GmbH 1 shared session